These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38958913)

  • 1. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
    Wright GC; Mysler E; Kwok K; Cadatal MJ; Germino R; Yndestad A; Kinch CD; Ogdie A
    Rheumatol Ther; 2024 Jul; ():. PubMed ID: 38958913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials.
    Tesser J; Gül A; Olech E; Oelke K; Lukic T; Kwok K; Ebrahim A
    Arthritis Res Ther; 2023 Nov; 25(1):214. PubMed ID: 37919780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
    Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
    Winthrop KL; Yndestad A; Henrohn D; Danese S; Marsal S; Galindo M; Woolcott JC; Jo H; Kwok K; Shapiro AB; Jones TV; Diehl A; Su C; Panés J; Cohen SB
    Rheumatol Ther; 2023 Apr; 10(2):357-373. PubMed ID: 36526796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
    Winthrop KL; Curtis JR; Yamaoka K; Lee EB; Hirose T; Rivas JL; Kwok K; Burmester GR
    Rheumatol Ther; 2022 Feb; 9(1):243-263. PubMed ID: 34870800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
    Hansen KE; Mortezavi M; Nagy E; Wang C; Connell CA; Radi Z; Litman HJ; Adami G; Rossini M
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221142346. PubMed ID: 36601090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
    Citera G; Jain R; Irazoque F; Madariaga H; Gruben D; Wang L; Stockert L; Santana K; Ebrahim A; Ponce de Leon D
    Rheumatol Ther; 2024 Feb; 11(1):35-50. PubMed ID: 37925660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
    Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
    RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
    Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
    Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Curtis JR; Yamaoka K; Chen YH; Bhatt DL; Gunay LM; Sugiyama N; Connell CA; Wang C; Wu J; Menon S; Vranic I; Gómez-Reino JJ
    Ann Rheum Dis; 2023 Mar; 82(3):331-343. PubMed ID: 36600185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
    Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
    RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
    Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
    Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
    Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
    Dougados M; Taylor PC; Bingham CO; Fallon L; Brault Y; Roychoudhury S; Wang L; Kessouri M
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36814062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
    Kristensen LE; Deodhar A; Leung YY; Vranic I; Mortezavi M; Fallon L; Yndestad A; Kinch CD; Gladman DD
    Rheumatol Ther; 2024 Jun; 11(3):487-499. PubMed ID: 38696034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R; Isaacs JD; Chen LA; Wang W; Marren A; Kwok K; Wang L; Chan G; Su C
    Dig Dis Sci; 2021 Aug; 66(8):2732-2743. PubMed ID: 32816215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.